Hims & Hers investors get notice in proposed securities fraud class action
A law firm says investors who lost money in Hims & Hers Health, Inc. may seek to lead a proposed securities fraud class action tied to alleged disclosures and business practices.
Glancy Prongay Wolke & Rotter LLP said in a PR Newswire release that investors who lost money in Hims & Hers Health, Inc. may seek to lead a proposed securities fraud class action.
The release says no class has been certified. It also says the case concerns allegations about how the telehealth company described its business and handled consumer data.
What the notice says
The press release says the proposed class period runs from Aug. 4, 2025, through July 29, 2026. It also says the lead-plaintiff deadline is Nov. 2, 2026.
According to the release, the complaint alleges Hims & Hers shared consumers’ health information with third-party advertising platforms. It also alleges the company charged consumers for prescriptions almost immediately after they submitted intake forms, even as it told them they could consult with a medical provider to find the treatment that is “right for them.”
The notice says the alleged conduct exposed the company to regulatory scrutiny and that the company was reasonably likely to incur fees and penalties. It says positive statements about the company’s business, operations and prospects were materially misleading or lacked a reasonable basis.
Context
The source is a law-firm press release, not a court filing or a statement from Hims & Hers. The release says it is seeking investors to participate in the case, a step before a lead plaintiff is chosen in U.S. securities litigation.
The notice names Hims & Hers Health, Inc., a public company whose shares trade under the ticker HIMS. It does not include a response from the company.
What happens next
According to the release, investors with losses who want to seek appointment as lead plaintiff must act before the Nov. 2 deadline. The notice says contact details for the law firm are available in the release.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.